Bionova Scientific Expands Capacity And Enters Advanced Therapies Market

• Third Cytiva FlexFactory manufacturing platform will help the CDMO meet the rising demand for genomic medicines
• Cytiva’s Fast Trak process development services will accelerate Bionova’s production processes while ensuring compliance with stringent regulatory standards

Bionova Scientific, a contract development and manufacturing organization (CDMO), is entering the advanced therapy manufacturing space. The company is installing its third FlexFactory manufacturing platform from Cytiva, a Danaher company and a leader in the life sciences industry, to help meet the surging demand for advanced therapies, while maintaining their core monoclonal antibody (mAb) business. Bionova will also use Cytiva’s Fast Trak process development services to help advance their entry into genomic medicines.

Fabio Fonseca, Ph.D. Senior Director, pDNA Process Development, Bionova Scientific, says: “Using Cytiva’s end-to-end solutions, we’ll have an exceptional platform to support the manufacture of genomic medicines. Together with our team and technology stack, we are well positioned to deliver plasmid DNA with speed, quality and patient safety.”

Ludovic Brellier, President of Hardware Solutions, Cytiva, says: “Our true value lies in our deep process expertise in accelerating our customer’s process development through to commercial manufacturing. Having the flexibility and support to scale while meeting strict regulatory compliance will help Bionova develop a competitive edge in a growing market.”

The FlexFactory platform for advanced therapies offers substantial benefits that reduce business risks, increase operational speed, faster product ramp-up, and enhance flexibility. Its built-in compliance features and robust quality controls helps improve regulatory adherence and minimize production issues, while its modular setup allows rapid adaptation to market shifts. Cytiva’s Fast Trak process development services will help Bionova accelerate their molecule through clinical development.

Bionova’s new facility in The Woodlands, Texas celebrated its grand opening on May 29, 2025, with the new FlexFactory slated for delivery in Q3 2025.

Find more information on the Cytiva FlexFactory manufacturing platform here (https://www.cytivalifesciences.com/en/us/solutions/bioprocessing/products-and-solutions/enterprise-solutions/flexfactory).

Learn more about Bionova Scientific’s new offerings here (https://bionovascientific.com/services/plasmid-dna/).

About Bionova Scientific
Bionova Scientific partners with innovators in the biologic industry to bring life-changing therapies to market. Founded in 2014 and acquired by Asahi Kasei Group in 2022, Bionova Scientific offers customers access to superior tools and technologies and an unwavering commitment to quality delivered with scientific excellence across the entire lifecycle. Bionova offers integrated CDMO services that span cell line development, process development to commercial cGMP manufacturing of complex proteins and antibodies. Our experienced scientists bring proven expertise to overcoming discovery to first-in-human development challenges and scale-up. Bionova is a flexible and collaborative partner that has worked with leading biotechnology innovators from its new state-of-the-art facility in the San Francisco Bay Area. For more information, visit bionovascientific.com

About Cytiva
At Cytiva, our mission is to advance and accelerate the development of therapeutics. With 15 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers. For more information, visit cytiva.com.

Cytiva is proud to be part of Danaher, a leading life sciences and diagnostics innovator committed to accelerating the power of science and technology to improve human health. For more information, visit www.Danaher.com